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Abstract: Medical treatment of mycetoma depends on
its fungal or bacterial etiology. Clinically, these entities
share similar features that can confuse diagnosis, causing
a lack of therapeutic response due to inappropriate
treatment. This review evaluates the response to available
antimicrobial agents in actinomycetoma and the current
status of antifungal drugs for treatment of eumycetoma.
Introduction
Mycetoma is a potentially serious, devastating, chronic,
inflammatory disease caused by aerobic actinomycetic bacteria
(actinomycetoma) or fungi (eumycetoma). The worldwide inci-
dence of actinomycetoma and eumycetoma varies from country to
country and region to region, but this infection is predominant in
countries that are located between 30uN and 15uS. Most cases of
mycetoma occur in Sudan, Venezuela, Mexico, and India. Sudan
has the highest incidence of eumycetoma (up to 70%). In Mexico,
actinomycetoma predominates in about 97% of cases [1]. The
clinical picture of both infections is quite similar. To achieve cure,
it is important to define the fungal or bacterial etiology because
treatment for each is completely different. Actinomycetoma is
currently treated with antibiotics, which can be used alone or in
different combinations depending on the severity, dissemination,
and location of the disease. Medical cure is generally achieved if
the patient is properly treated [2]. In contrast, treatment of
eumycetoma consists of antifungals and surgical excision [3].
Medical cure is more difficult to obtain and the extension and
location of the disease may lead to chronic progressive lesions that
often lead to amputation [4]. However, in both forms of
mycetoma, prolonged treatment is needed. Our objective is to
present the current status of medical therapy of mycetoma and
the best antibiotic and antifungal options available for its
management.
Methods
Most of the literature we reviewed related to treatment was
based on case reports and in vitro and in vivo studies of drug
susceptibilities. We assessed and collected leading articles on drugs
that are available and have been successfully used in patients with
actinomycetoma and eumycetoma. Adverse effects, drug interac-
tions, dose, and duration of treatment were considered. We
appraised publications most useful for readers interested in the
medical management of this neglected disease.
Actinomycetoma
Causative agents
Three genera (Nocardia, Streptomyces, and Actinomadura)
comprise the most frequent causative agents of actinomycetoma.
Etiological agents of actinomycetoma include Nocardia brasilien-
sis, N. asteroides, N. caviae, N. farcinica, N. transvalensis, N.
dassonvillei, N. mexicana, N. veterana, Actinomadura madurae, A.
pelletieri, A. latina, Streptomyces somaliensis, and S. sudanensis.
New species of Nocardia that have been reported to cause
actinomycetoma are N. harenae and N. takedensis [5,6].
In vitro susceptibility data
Studies of sensitivity of N. brasiliensis to different antimicrobials
and antibiotics have been reported in vitro and in vivo [7–10]. A
study by Gomez et al. demonstrated that the best inhibitory effect
occurs with aminoglycosides (100% susceptibility to amikacin,
gentamicin, isepamicin, netilmicin, and tobramycin); however, all
strains were resistant to streptomycin and kanamycin. Nocardia
strains were also susceptible to linezolid in 100% of cases and to
sulfonamides (trimethoprim-sulfamethoxazole) in 83% [10].
Amoxicillin-clavulanate showed an inhibitory effect of 97%. Other
oxazolidinones have been evaluated in the laboratory and found
effective for future treatment in cases that could be resistant to
other antimicrobials [11].
The susceptibility of 30 strains of N. brasiliensis isolated from
patients with actinomycetoma was determined using econazole,
imipenem, and meropenem, both alone and combined with
clavulanic acid. MIC50 and MIC90 values for econazole were 2
and 4 mg/ml, respectively. For imipenem, values were 64 and
64 mg/ml, respectively. Only seven isolates had a minimum
inhibitory concentration (MIC) of 2 mg/ml. Regarding merope-
nem, MIC values were 2 and 8 mg/ml with 16 out of 30 isolates
exhibiting an MIC of 2 mg/ml. The addition of clavulanic acid to
the carbapenems did not significantly change MIC values [8].
Because of the cost of carbapenems, it is necessary to determine if
the isolated strain is susceptible to these antibiotics.
Molecular studies have also been useful to identify the species of
the infecting organism with greater specificity [7,9].
Animal models
Animal models have been successfully used to study the
pathogenic mechanism of actinomycetoma and the therapeutic
efficacy of diverse antimicrobials. Experimental N. brasiliensis
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actinomycetoma infection was induced by inoculation in the
footpad of immunocompetent and athymic nude homozygous and
heterozygous Lewis rats. Classic actinomycetoma lesions occurred
in the infected foot of the immunocompetent rats. After 20–25
days, the lesions began to heal. A more active infection was found
in homozygous athymic rats, and some animals died because of
dissemination of the infection with organ involvement. Histopath-
ological examination showed an infiltrate mainly of polymorpho-
nuclear cells; after 20 days, the infiltrate was composed mostly of
histiocytes, lymphocytes, fibroblasts, and Langhans cells. The
presence of grains was observed after 15 days in heterozygote
Lewis rats, but not in homozygous nude rats [12].
Studies in BALB/c mice have allowed analysis of the
inflammatory mechanisms and therapeutic effect of diverse
antimicrobials [13]. Since combination therapy seems to work
better for actinomycetoma, amikacin, SXT, amoxicillin-clavulanic
acid, and linezolid were analyzed to determine the effect of drug
combinations on N. brasiliensis [10]. Some of the combinations
tested, particularly amoxicillin-clavulanic acid in combination with
linezolid, showed synergistic activity.
Because of the ethical and patient selection difficulties in
carrying out prospective clinical trials in endemic areas, the animal
model becomes a useful alternative to determine which antimi-
crobials could be therapeutically effective in human infection.
Clinical data
Actinomycetoma frequently affects the feet and legs; in Mexico,
the back is the second most frequent location affected, but different
body parts may also be affected. The infection involves
subcutaneous tissues and can disseminate to underlying structures,
such as bone and organs. It is characterized by a painless, firm
mass with nodules, abscesses, fistulae, and draining sinuses
discharging a syrup-like filamentous exudate that contains aerobic
grains of the causative organism. The differential diagnosis
includes other bacterial infections causing osteomyelitis, tubercu-
losis, other mycobacterial infections, subcutaneous and systemic
mycoses, and neoplasia [2].
In contrast to eumycetoma, in actinomycetoma, surgery is
seldom used. Most cases respond to medical therapy, although
some require prolonged administration of antimicrobial combina-
tions (for weeks or months) (Table 1) [2].
Current treatment of actinomycetoma
Effective medical treatment of actinomycetoma began in the
early 1940s and 1950s with the use of sulfonamides and diamino
diphenyl sulphone (DDS), achieving cure in some cases. In the
1960s, trimethoprim-sulfamethoxazole (TS) became standard
treatment for actinomycetoma. This drug was given for 3–4
months, and in some cases, for longer periods. Other antibiotics,
such as streptomycin, isoniazid, rifampin, and minocycline, have
been added in isolated cases that did not respond to TS [14,15].
There are no comparative studies of the efficacy of these drugs in
combination with TS.
Treatment with TS continued in the 1970s [16]. In 1982, a case
of severe actinomycetoma successfully treated with a combination
of amikacin sulphate and TS was reported [17]. The patient was a
19-year-old man with multiple lesions and ulcers on his chest wall
and with pulmonary involvement accompanied with malaise. The
causative organism was identified as N. brasiliensis and was
isolated from skin lesions, pleural effusion fluid, and blood. Skin
biopsy from the affected site revealed multiple granulomas and
Nocardia grains. The colony was sent to the American Type
Culture Collection (ATCC) reference database for characteriza-
tion and further study. The strain was named HUJEG-1
(N. brasiliensis ATCC 700358). The complete sequence of this
strain was achieved in 2012 [18].
Because of the infection severity and its dissemination, the
authors sought treatment alternatives and selected amikacin
sulphate because of its in vitro inhibitory activity against N.
asteroides. This drug was combined with TS and given as follows:
amikacin 15 mg/kg/day intramuscularly (IM) divided into two
daily doses for 3 weeks simultaneously with TS 8/40 mg/kg/day
orally for 5 weeks. At the end of this time, the patient obtained an
improvement of 90% and all pulmonary lesions disappeared. He
was released from the hospital and did not return for evaluation,
nor did he continue any treatment. About a year later, the patient
was seen, and he was completely cured.
The results obtained in this patient led to a prospective study
with this combination scheme in severe cases of actinomycetic
mycetoma that did not respond to TS alone [19]. Up to 1989, a
total of 25 patients unresponsive to previous therapy or with
extensive involvement and/or risk of dissemination to underlying
organs were treated. Depending on the severity and extension of
disease, some patients were treated as inpatients and others as
outpatients. The combination was administered in 5-week cycles (3
weeks of amikacin sulphate intramuscularly together with 5 weeks
of oral TS). Audiometry and creatinine clearance were performed
before and after each cycle of amikacin sulphate. Depending on
the clinical response, this cycle of treatment was consecutively
repeated for up to four cycles. All patients in this group were cured
except for one who after 3 months developed a recurrence that
required further treatment [20].
To date, the response to this combination has been encouraging
(see Figure 1) [2], achieving a cure rate of about 90% (56 patients).
Twenty percent of these patients developed minimal or moderate
auditory changes detected by audiometry. In one patient, it was
severe and detected clinically. In three patients, the medication
was stopped; in one because of drug allergy, another due to
development of bacterial resistance, and in a third because of
recurrence 2 years after remission. Treatment in this patient was
continued with a combination of TS, moxifloxacin, netilmicin, and
imipenem, and he was cured.
Different antibiotics have been assayed in vitro, ex vivo, and in
experimental N. brasiliensis actinomycetomas to find treatment
alternatives. Among these are TS, amikacin, other aminoglyco-
sides, amoxicillin-clavulanic acid, minocycline, moxifloxacin, line-
zolid, and carbapenems [7,10,11,21–23]. Most of the recalcitrant
cases in patients have responded well to amikacin/TS and only a
few had further treatment with imipenem and/or carbapenem [2].
Eumycetoma treatment in Mexico
Eumycetoma occurs in Mexico in 3.48% of cases [1].
Treatment is based on prolonged administration of imidazoles
such as itraconazole, alone or combined with terbinafine [24].
Posaconazole and voriconazole are available but are expensive,
and their therapeutic efficacy has not been assayed. Amphotericin
B is rarely used. The combination of medical and surgical
treatment is the usual management of this fungal infection.
Adverse effects
Amikacin sulphate or the administration of any aminoglycoside
requires close clinical observation with audiometry and renal
function tests every 3 to 5 weeks to detect auditory and
nephrotoxicity and adjust dosing accordingly. Loop diuretics
should be avoided with amikacin sulphate because of potential
cochlear damage [25]. Cephalothin may increase the risk of
aminoglycoside nephrotoxicity [26].
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Side effects of other currently used antimicrobials should be
considered. Other nephrotoxic antibiotics (vancomycin, merope-
nem) in combination with aminoglycosides must be avoided
because they can increase potential nephrotoxicity. Dosing must
be adjusted for renal function and for haemofiltration.
Imipenem and meropenem should not be prescribed to patients
who are allergic to penicillin and other b-lactam antibiotics
[27].
Mild adverse events with linezolid are diarrhea, headache, and
nausea. An important adverse effect, myelosuppression, has been
reported with high and prolonged doses. Blood parameters return
to normal after discontinuing the drug and a complete blood count
must be performed weekly. Neurological symptoms, such as
peripheral and optic neuropathy, can develop [28,29].
Trimethoprim/sulfamethoxazole can produce dermatologic
reactions, usually due to hypersensitivity, such as rash, pruritis,
photosensitivity reactions, exfoliative dermatitis, erythema
nodosum, and haemolytic anemia. Patients should be well
hydrated and with an alkaline urine because sulfamethoxazole
may cause sulfa crystalluria. Gastrointestinal and other
haematologic, renal, hepatic, metabolic, and nervous system
effects should be evaluated before and during drug adminis-
tration [30]. Antibiotics and doses that are currently available




Causative agents of eumycetoma are classified into those that
produce black grains and those that produce white or grayish
grains: Acremonium falciforme, Acr. kiliense, Acr. recifei, Asper-
gillus flavus, Asp. nidulans, Cladophialophora bantiana, Cochlio-
bolus spicifer, Corynespora cassicola, Curvularia geniculata, Cur.
lunata, Cylindrocarpon cyanescens, Cyl. destructans, Drechslera
rostrata, Exophiala jeanselmei, Exserohilum rostratum, Fusarium
spp., Fusarium moniliforme, F. oxysporum, F. solani, Lepto-
sphaeria senegalensis, L. tompkinsii, Madurella mycetomatis, M.
grisea, M. fahalii, Neotestudina rosatii, Phaeoacremonium krajde-
nii, Phialophora cyanescens, Plenodomus avramii, Polycytella
hominis, Pseudallescheria boydii, Pseudochaetosphaeronema lar-
ense, Pyrenochaeta mackinnonii, P. romeroi, and Scedosporium
apiospermum. Four etiological agents cause more than 90% of the
eumycetomas worldwide. These are M. mycetomatis, M. grisea,
Pseudosporium boydii, and L. senegalensis [31,32].
In vitro susceptibility data
Several in vitro studies have been conducted on fungal
organisms that commonly cause eumycetoma. Most of the studies
were of M. mycetomatis and Scedosporium boydii complex (Sc.
apiospermum, Sc. boydii, Sc. aurantiacum) and a few agents of
Table 1. In vitro susceptibility, clinical efficacy, and dose of current antibiotics for actinomycetoma and antifungal agents against
M. mycetomatis.
Antibiotics In vitro Human infection Dose
Sulfonamides DDS (4,4
diaminodiphenyl-sulfone)
No data Effective 100–200 mg/day single dose
Trimethoprim-Sulfamethoxazole (TS) Active Effective 8 mg/40 mg
Amikacin sulphate-TS Active Effective Amikacin: 15 mg kg/day IM or IV in two daily doses; TS
as above
Netilmicin-TS Active Effective Netilmicin 300 mg/day IM single dose; TS as above
Minocycline Active Effective in 70% 200 mg/day PO in divided dose
Amoxicillin-clavulanate Active Effective 500 mg/125 mg PO; tid for 3 to 6 months
Linezolid Active Effective 600 mg PO twice daily
Fosfomycin Active Effective 100–200 mg/kg/day q6-8 h IV or PO in 21-day cycles.




500 mg IV q8 hours; not to exceed 50 mg/kg/day or
4 g/day
Meropenem Active Effective 500 mg IV q8 hr; not to exceed 2 g IV daily





Moxifloxacin Active Effective 400 mg/day IV or PO
Antifungal agents
Amphotericin B Moderate activity Not effective
Fluconazole Limited activity Not effective
Ketoconazole Active Variable efficacy 400–800 mg
Itraconazole Active Variable efficacy 200–400 mg
Voriconazole Active Effective in few case reports 200 mg
Posaconazole Active Effective in few cases
Isavuconazole Active No data
Echinocandins Not active No data
Terbinafine Moderate activity No data
Possible drug interactions, history of drug allergies, and co-morbidities should be analyzed in all drugs.
IM, intramuscularly; IV, intravenous; PO, orally; tid, three times daily.
doi:10.1371/journal.pntd.0003218.t001
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phaeohyphomycosis that can cause mycetoma such as Exophiala
jeanselmei [33–40]. Almost no data have been reported for
Falciformispora senegalensis (synonym: L. senegalensis) and
Medicopsis romeroi (synonym: P. romeroi) [41]. van de Sande
and colleagues have conducted several studies on M. mycetomatis
susceptibility to many of the currently available antifungals. In
vitro testing was done by known methods for filamentous fungi.
These methods included the CLSI broth dilution method and the
colorimetric Sensititre YeastOne test, as well as the viability-based
XTT test. The three methods were compared by testing 36 isolates
of M. mycetomatis against six antifungals: amphotericin B,
ketoconazole, fluconazole, itraconazole, voriconazole, and 5-
flucytosine [34]. The Sensititre test was comparable to the CLSI
method but produced lower MICs when compared to the viability-
based XTT test. This was more obvious with the azoles. The most
active antifungals, in vitro, were ketoconazole and the extended-
spectrum triazoles, itraconazole and voriconazole. Amphotericin B
had a median MIC of 1 mg/mL, while fluconazole had limited
activity, and 5-flucytosine had no activity against M. mycetomatis.
The echinocandins, caspofungin, micafungin, and anidulafungin
showed no activity in vitro against 17 isolates of M. mycetomatis
utilizing the XTT method [35]. However, another study of three
isolates of M. mycetomatis against anidulafungin using the CLSI
method had an MIC of 1 mg/mL [42].
The role of melanin in fungal resistance to antifungals in M.
mycetomatis is not clear. One study has shown a several-fold
increase in MICs to ketoconazole and itraconazole with the
addition of melanin to the culture media [43]. Posaconazole and
isavuconazole have good activity against M. mycetomatis, Sc.
apiospermum and E. jeanselmei. MICs against M. mycetomatis
were in the range of 0.016 to 0.25 mg/mL [36,44].
The allylamine antifungal, terbinafine, showed moderate
activity against M. mycetomatis and variable activity against Sc.
apiospermum [36,45–47]. Several in vitro studies have indicated
low MICs for itraconazole and voriconazole to several strains of
Sc. apiospermum [37,39,45,48]. Several agents of phaeohypho-
mycosis, including E. jeanselmei, are susceptible in vitro to
itraconazole, voriconazole, and posaconazole [39,40,49,50].
Standardization of the testing methodology is required to be
able to compare evidence from various studies against filamentous
fungi. Many of these fungi do not sporulate or may have variable
sporulation within different strains of the same species. Using a
hyphal inoculum may not be similar to a conidial inoculum, and
therefore gives different results [51]. The extended spectrum
triazoles and ketoconazole have the best activity against M.
mycetomatis, while ketoconazole has limited or variable activity
against Sc. boydii complex and phaeohyphomycetes.
Animal models
Few experimental animal models on the development of M.
mycetomatis eumycetoma infection have been published. Data
regarding experimental fungal infections that can cause mycetoma
Figure 1. Clinical outcome of patient with actinomycetoma treated with amikacin and trimethoprim/sulfamethoxazole, before (a)
and after (b) therapy.
doi:10.1371/journal.pntd.0003218.g001
PLOS Neglected Tropical Diseases | www.plosntds.org 4 October 2014 | Volume 8 | Issue 10 | e3218
come from a few successful models (athymic mice, BALB/c mice
and goat); however, none of these have evaluated the therapeutic
effect of antifungals on M. mycetomatis infection [52,53]. Animal
models for therapy of infections due to S. boydii complex and
agents of phaeohyphomycosis are several, including murine, rat,
and guinea pig [54,55]. Sc. apiospermum experimental infection in
mouse and guinea pig has shown the efficacy of voriconazole and
posaconazole [56–58]. A high dose of posaconazole was required
for efficacy in a murine model of disseminated Sc. apiospermum
infection, while itraconazole was not effective [57]. Higher MIC to
voriconazole correlated with failure of experimental therapy in
one study [54]. Several phaeohyphomycetes, including Exophiala
species, were responsive to itraconazole and posaconazole in an
experimental murine infection [59]. Posaconazole demonstrated
the best activity in these animal studies [60,61].
Clinical data
Published studies indicate the need for combined medical and
surgical therapy to achieve success in fungal mycetoma. Factors
that determine therapy outcome include extent of tissue and bone
involvement, site of the disease, and antifungal therapy. It is not
yet clear if the extent of surgical debridement and the type and
duration of antifungal therapy alter outcome [4]. However, near
complete surgical excision and prolonged antifungal therapy is
more likely to succeed. Timing of surgery in relation to antifungal
therapy is not well established. One prospective study indicates
that medical therapy may limit the disease and make complete
excision of the lesions more feasible [3].
Current treatment of eumycetoma
As neglected diseases, mycetoma in general and fungal
mycetoma in particular have received little attention in the
development of specific therapeutics. All currently used drugs
against causative agents of eumycetoma were developed and
studied with other, more common fungi [62]. For several decades,
systemic antifungal therapy has been limited to a few drugs that
are potentially toxic and delivered parenterally. Amphotericin B
deoxycholate was widely used despite its toxicity. However, a wide
range of antifungal agents have been approved and marketed for
various fungal infections [62]. These include less toxic lipid
formulations of amphotericin B, second and third generation
azoles, terbinafine and echinocandins. The newer azoles are
broad-spectrum and oral, with good bioavailability and low
toxicity [63]. These agents are particularly attractive for prolonged
outpatient therapy, which is typically needed in a chronic fungal
infection such as eumycetoma; however, there are limited in vitro
and in vivo studies. Clinical data are almost exclusively from case
reports and a small number of case series. Prospective clinical
studies are needed to evaluate the therapeutic potential of these
antifungals.
Amphotericin B was the only systemic antifungal available for
almost three decades. It was not widely used for eumycetoma
because of significant toxicity and the need to be given
parenterally for prolonged periods. Lipid-associated amphotericin
B was tried at the Mycetoma Research Centre in Sudan in four
patients, but the results were disappointing. One patient had acute
renal failure; treatment was stopped and he recovered. The other
three patients had courses of 6 weeks duration with no dramatic
response, and viable organisms were cultured from the lesions.
The imidazole ketoconazole, introduced in the early 1980s, was
a breakthrough in systemic antifungal therapy. It is active against
Candida and several other fungi and can be administered orally.
Mahgoub and Gumaa published their experience with ketocona-
zole therapy in 13 patients with mycetoma due to M. mycetomatis
from Saudi Arabia and the Sudan. Doses ranged from 200 to
400 mg daily, and the therapeutic response was variable: ten
patients had a good response and three did not [64]. The follow-
up period was short in half the patients; therefore, the frequency of
relapse could not be determined. Afterwards, reports of variable
responses with ketoconazole in different parts of the world were
published [65,66]. In a report from India, six out of ten patients
were reported cured of fungal mycetoma after prolonged therapy
with ketoconazole (8 to 24 months) [66]. However, recently, the
use of ketoconazole has been limited by the United States Food
and Drug Administration and the European Medicines Agency
(EMA) due to its hepatic and adrenal toxicity. Ketoconazole
should not be used as first-line treatment. It is recommended only
for the treatment of certain life-threatening fungal infections
(endemic mycoses) when alternative antifungal therapies are not
available or tolerated [67]. Fluconazole is not an effective therapy
for eumycetoma and is currently not used for treatment [68].
Itraconazole was released in the early 1990s and became the
most commonly used drug for the treatment of eumycetoma in
places where it was affordable. The bioavailability of itraconazole
is variable, and absorption is related to stomach acidity and food.
Reports indicate a clinical response to itraconazole in patients with
eumycetoma [3,69–71]. These are mostly retrospective case series
or case reports that suggest a variable response. In one prospective
non-comparative study of medical therapy with itraconazole for 12
months followed by surgical excision in 13 subjects, most patients
had a favorable outcome [3].
Limited data is available on the new classes of antifungals
(Table 1). Few case reports show a good response to voriconazole
[72,73]. Treatment with posaconazole was successful in one case
and stable in another due to M. mycetomatis, three cases due to M.
grisea were successful, and one case due to Sc. apiospermum had a
partial improvement [74]. Duration of therapy and extent of
surgical debridement was variable among these cases.
Terbinafine given in a high dose was successful in a few cases of
eumycetoma and in two cases of disseminated E. jeanselmei
infection [75–76]. In a study of 23 patients, terbinafine at a high
dose of 500 mg twice daily for 24–48 weeks resulted in 25% cure
and 55% improvement of patients [77]. Terbinafine was not
effective in deep-seated infections due to Sc. apiospermum [78,79].
Both voriconazole and posaconazole were reported to be
efficacious in disseminated infections due to Sc. apiospermum
[80–85]. There are no clinical data on the efficacy of echino-
candins or the investigational triazole isavuconazole.
Adverse effects
It is important to evaluate possible drug interactions of azoles.
Antacids may reduce their absorption, and azoles may cause
edema when calcium channel inhibitors are used. Hypoglycemia
may occur with concomitant use of sulfonylureas. Azoles may
increase plasma concentrations of tacrolimus and cyclosporine at
high doses and they can also increase digoxin levels and plasma
levels of midazolam and triazolam. Rhabdomyolysis has been
reported with cholesterol-lowering drugs (lovastatin and simvasta-
tin) and severe cardiac arrhythmias and possible sudden death
with cisapride. Co-administration with phenytoin, rifampin, and
H2 receptor antagonists causes a reduction in azole plasma levels.
Imidazoles can increase the anticoagulant effect of warfarin.
Simultaneous treatment with warfarin and imidazoles should be
carefully monitored. The patient must avoid alcohol consumption,
and liver function should be periodically monitored [24].
Notable adverse effects of ketoconazole are hepatotoxicity,
gynecomastia, lip dryness and ulceration, skin hyperpigmentation,
and decreased libido. Itraconazole is contraindicated in patients
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with evidence of ventricular dysfunction such as congestive heart
failure or a history of congestive heart failure [86].
Posaconazole can cause fever, diarrhea, nausea, vomiting, and
headache. Other adverse events include hypokalemia, rash,
thrombocytopenia, and abdominal pain. Liver function tests
should be performed at baseline and throughout therapy to
monitor possible liver damage. Treatment should be discontinued
if serious liver abnormalities occur. Rare serious adverse events are
hemolytic uremic syndrome, thrombotic thrombocytopenic pur-
pura, pulmonary embolus, adrenal insufficiency, and allergic and/
or hypersensitivity reactions. Prolongation of the QT interval may
be seen [87].
Common side effects of voriconazole are visual alterations,
fever, rash, vomiting, nausea and diarrhea, headache, sepsis,
peripheral edema, abdominal pain, and respiratory disorders [24].
Conclusion
The therapeutic outcome of mycetoma depends on the bacterial
or fungal etiology of the infection; factors such as the infecting
agent; and the patient’s social and economic status, cultural
background, nutrition, therapeutic compliance, and resistance to
previous therapies; and the extension and location of the disease
are important.
Actinomycetoma must be treated with TS alone or in
combination with other available antibiotics. Amikacin has been
proven effective in disseminated infections or cases resistant to
previous therapy. Renal and auditory evaluations are essential.
Carbapenems are useful in some disseminated infections. Amox-
acillin-clavunate can be used in some cases and during pregnancy.
Most patients with eumycetoma are treated with either
ketoconazole or itraconazole. Itraconazole 200–400 mg daily for
6 months is used to create a good fibrous capsule around the
lesion, followed by wide local excision, continuing itraconazole
200–400 mg daily until cure is achieved. Cure is defined by the
disappearance of the mass and all sinuses, normal ultrasound, and
negative mycology findings. The decision to stop therapy is
determined by complete sinus healing, disappearance of the
eumycetoma mass clinically and radiologically by CT scan or
MRI, and absence of the infecting agent. Other antifungal agents
that can be used as second-line treatment include voriconazole
and posaconazole.
Looking Forward
Actinomycetoma requires prompt diagnostic procedures to
define the etiological agent. Precise identification of species by
molecular techniques can achieve this goal and provide knowledge
for testing the antimicrobial susceptibility patterns of each species
of aerobic actinomycetes to determine the best drug regimen for
clinical use. Future universal availability of these techniques in
endemic areas with actinomycetoma will facilitate this objective.
There are currently no treatment guidelines for eumycetoma.
Treatment is based on personal experience and a few case reports
or case series. There is a pressing need to develop guidelines. The
lack of prospective randomized clinical trials on fungal therapeu-
tics makes the choice and duration of treatment of eumycetoma
with antifungal agents difficult. Multicenter clinical trials to
develop novel antifungals are required as current drugs are of
limited efficacy, have adverse effects, and are expensive. Drug
choice in eumycetoma is largely determined by availability and
cost.
The International Mycetoma Center in Sudan and centers in
other countries such as the Netherlands, England, Switzerland,
and Mexico are joining efforts to design clinical studies to select
and evaluate the best therapeutic regimes for mycetoma.
In February 2013, a meeting was convened in Geneva,
supported by the Drugs for Neglected Diseases initiative (DNDi),
to highlight disease awareness and propose inclusion of this
infection in the list of neglected tropical diseases (NTDs) of the
World Health Organization. Experts from Sudan, United
Kingdom, the Netherlands, Mexico, and Switzerland participated
in that event, and the Mycetoma Consortium was established. In
May 2013, the proposal led by Professors Ahmed Fahal and El
Sheikh Mahgoub and other researchers had a safe landing at the
WHO, and by July 2013 mycetoma was included in the WHO
NTDs list. This action will increase awareness and facilitate and
promote international studies on new effective antifungal and
antibacterial agents for the treatment of mycetoma.
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Box 1. Key Learning Points
N Current management alternatives in the medical treat-
ment of actinomycetoma are successful in most cases.
N Knowledge of the different antibiotic susceptibility
patterns of different pathogenic species of actinomy-
cetes is useful for selecting the best treatment.
N Combination treatments in actinomycetoma have been
successful in recalcitrant cases.
N Drug adverse effects and interactions in mycetoma
therapy are factors that should be considered
N Traditional and new azoles are the current potential
alternatives for medical treatment of eumycetoma, but
large controlled studies are lacking.
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